AltiVate Reverse Glenosphere with RAVN Technology
ENCORE MEDICAL, L.P. · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-02 for K263086, the AltiVate Reverse® Glenosphere with RAVN™ Technology, submitted by Encore Medical L.P. of Austin, TX. The device falls under regulation 888.3660, device classification name Shoulder Prosthesis, Reverse Configuration, with classification product code PHX and subsequent product code KWS; the regulation medical specialty and 510(k) review panel are both Orthopedic. The application was received 09/02/2026 and was not reviewed by a third party.
SESE in the 510(k) pathway denotes clearance as substantially equivalent to a predicate, not premarket approval of a new device. The record does not describe the specific component change, the predicate device, or any clinical data supporting the comparison; those details would sit in the underlying 510(k) review documents rather than the summary page. The page also lists no combination product status and no authorized predetermined change control plan, and the public record carries no statement text.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263086
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- ENCORE MEDICAL, L.P.
- Product code
- PHX
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Shoulder Prosthesis, Reverse Configuration.
- Applicant
- ENCORE MEDICAL, L.P.
- Product code
- PHX
- FDA device class
- 2
FDA decision timeline
K263086 received
Application receipt date recorded by FDA.
K263086 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PHX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| FX Shoulder Solutions, Inc. | 510(k) clearance | Nov 5, 2026 | FDA | |
Veritas Shoulder SystemK263421 | restor3d Inc. | 510(k) clearance | Oct 22, 2026 | FDA |
| Restor3D | 510(k) clearance | May 19, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ENCORE MEDICAL, L.P.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Austin, TX
Sources and methodology
- Original FDA record: K263086
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
